Skip to main content
Premium Trial:

Request an Annual Quote

Olympus, Cangen, Thermo Electron, Kendro, Bruker Daltonics, HealthLinx, PerkinElmer, GenoLogics, Genpathway, Baylor College

Premium

Olympus, Cangen to Co-develop 'Hybrid' DNA/Protein Microarray-based Test for Lung Cancer

Cangen Biotechnologies and Olympus plan to co-develop a hybrid DNA- and protein-based diagnostic that can detect early-stage lung cancer, the firms said this week.

The alliance will provide Cangen access to Olympus' microarray technology to enable the DNA-based portion of the test. Terms also call for Olympusto "refine" and "further develop" its microarray technology to help Cangen develop the hybrid test. Technical details were not disclosed.

"This collaboration complements development efforts for our microarray technology and affords us the opportunity to commercialize that technology," Hiroyuki Yoshimori, division manager of Biomedical Business Incubation Division in Olympus, said in a statement.

Financial terms were not released.


Thermo to Sell $250M in Senior Notes to Help Pay for Kendro Acquisition Loan

Thermo Electron plans to sell $250 million of 5 percent senior notes due 2015, the company said this week.

Thermo said it will use the cash to pay $250 million of a $570 million credit line it entered when it acquired Kendro Laboratory Products earlier this month. Thermo acquired the company for $833.5 million in cash.

The Kendro business is expected to be folded into the Bioscience Technologies segment of Thermo's Life and Laboratory Sciences business unit, which focuses on the sample-prep portion of the laboratory workflow market.

Before being acquired by Thermo, Kendro was a business unit of SPX Corporation, where it designed, manufactured, marketed, and serviced a range of laboratory equipment for sample preparation, processing, and storage used in drug discovery and clinical laboratories.


Bruker's ClinProt Mass Spec Platform to Help HealthLinx Develop IVD Biomarker Assays

HealthLinx of Melbourne, Australia, will use Bruker Daltonics' mass spectrometry-based protein biomarker platform to develop diagnostic assays, the company said this week.

In collaboration with Bruker, HealthLinx plans to develop in vitro diagnostic tests for both research and clinical diagnostics using Bruker's MALDI-TOF mass spectrometer and its ClinProt magnetic bead sample preparation technology and software.

The first product to be developed is an ovarian cancer test based on four biomarkers discovered by HealthLinx. The company has also enlisted the Walter Eliza Hall Institute of Medical Research to develop monoclonal antibodies to these biomarkers, to be used with the Bruker platform. HealthLinx said it will seek FDA registration for the test "through industry partnerships for use as a pathology diagnostic."

Following validation, the companies will also seek to register the ClinProt platform as a diagnostic pathology device with the Australian government Therapeutic Goods Administration.


PerkinElmer to Pay 7-Cent Dividend to Stockholders

PerkinElmer's board yesterday agreed to issue a $.07 dividend to existing shareholders on Aug. 12, the company said last week.

The dividend applies to all shareholders of all record at the close of business on July 22, the company said.


GenoLogics to Distribute Open Software from ISB as Part of its Data Management Platform

GenoLogics will provide open source software from the Institute of Systems Biology as part of its ProteusLIMS lab information management system for proteomics, the Victoria, Canada-based company said last week.

Under the agreement, GenoLogics will try to enhance the functionality and usability of ISB's open source tools for genomics, proteomics, and high-speed cell sorting, as well as integrate them with its platform, ProteusLIMS, and support them.

ISB plans to extend the relationship as it develops new bioinformatics tools and GenoLogics extends its LIMS platform into systems biology.


Genpathway's Transcription Analysis Tech Helps Baylor College Find Breast Cancer Genes

Researchers at Genpathway and Baylor College of Medicine have used Genpathway's transcription analysis technology to identify genes involved in breast cancer, the San Diego-based company said this week.

The scientists used Genpathways's Factor Path assay, one of several transcription-based assays that measure transcription directly, rather than by RNA levels, to identify genes regulated by a protein overexpressed in breast cancer.

The assay identifies genomic DNA sequences that are functionally associated with a particular transcription factor or coregulator and quantifies the binding level of each factor across the genome. Another Genpathway assay, TranscriptionPath, showed that the genes identified are biologically relevant.

The study was published earlier this year in PNAS.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.